Cover Image

HARDBACK
$69.95



View/Hide Left Panel

94. Field MJ, Behrman RE, eds. Ethical Conduct of Clinical Research Involving Children. Washington, DC: The National Academies Press; 2004.

95. Lantos JD. The “inclusion benefit” in clinical trials. Journal of Pediatrics 1999; 134(2):130–131.

96. Silverman WA. Disclosing the “inclusion benefit.” Journal of Perinatology 2002; 22(4):261–262.

97. Choonara I, Conroy S. Unlicensed and off-label drug use in children: implications for safety. Drug Safety 2002;25(1):1–5.

98. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatrica 1999; 88(9):965–968.

99. Tyson JE, Knudson PL. Views of neonatologists and parents on consent for clinical trials. Lancet 2000;356(9247):2026–2067.

100. Manning DJ. Presumed consent in emergency neonatal research. Journal of Medical Ethics 2000;26(4):249–253.

101. Rogers CG, Tyson JE, Kennedy KA, Broyles RS, Hickman JF. Conventional consent with opting in versus simplified consent with opting out: an exploratory trial for studies that do not increase patient risk. Journal of Pediatrics 1998;132(4):606–611.

102. U.S. Department of Health and Human Services. 45 CFR Part 46: Protection of Human Subjects. Federal Register 2001;66(219):56775–56780.

103. Food and Drug Administration. Additional safeguards for children in clinical investigations of FDA-regulated products. Federal Register 2001;66(79):20589–20600.

104. Campbell AT. State regulation of medical research with children and adolescents: an overview and analysis. In: Field MJ, Behrman RE, eds. Ethical Conduct of Clinical Research Involving Children. Washington, DC: National Academies Press; 2004:320–387.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement